Financial reports
10-K
2023 FY
Annual report
27 Mar 24
10-Q
2023 Q3
Quarterly report
8 Nov 23
10-Q
2023 Q2
Quarterly report
9 Aug 23
10-Q
2023 Q1
Quarterly report
10 May 23
10-K
2022 FY
Annual report
15 Mar 23
10-Q
2022 Q3
Quarterly report
2 Nov 22
10-Q
2022 Q2
Quarterly report
11 Aug 22
10-Q
2022 Q1
Quarterly report
12 May 22
10-K/A
2021 FY
Annual report (amended)
11 Mar 22
10-K
2021 FY
Annual report
8 Mar 22
Current reports
8-K
Regulation FD Disclosure
28 Mar 24
8-K
Matinas BioPharma Reports 2023 Financial Results and Provides a Business Update
27 Mar 24
8-K
Matinas BioPharma Announces Positive in vivo Safety Data with its Oral LNC-Docetaxel Formulation
25 Mar 24
8-K
Regulation FD Disclosure
22 Mar 24
8-K
Other Events
22 Mar 24
8-K
Regulation FD Disclosure
26 Feb 24
8-K
Regulation FD Disclosure
20 Feb 24
8-K
Regulation FD Disclosure
9 Jan 24
8-K
In an acute psoriasis model, data show reductions in tissue IL-17A mRNA and improvement in clinical disease markers including skin lesions
27 Dec 23
8-K
Matinas BioPharma Provides Update to MAT2203 Regulatory and Development Pathway Following Feedback from FDA
21 Dec 23
Registration and prospectus
424B5
Prospectus supplement for primary offering
7 Jul 23
S-3
Shelf registration
9 Jun 23
S-8
Registration of securities for employees
31 Mar 23
S-8
Registration of securities for employees
1 Apr 22
S-8
Registration of securities for employees
26 Feb 21
424B5
Prospectus supplement for primary offering
10 Aug 20
S-3/A
Shelf registration (amended)
27 Jul 20
S-3
Shelf registration
2 Jul 20
S-8
Registration of securities for employees
20 Mar 20
424B5
Prospectus supplement for primary offering
13 Jan 20
Proxies
DEF 14A
Definitive proxy
19 Sep 23
PRE 14A
Preliminary proxy
8 Sep 23
DEF 14A
Definitive proxy
22 Sep 22
DEF 14A
Definitive proxy
17 Sep 21
DEF 14A
Definitive proxy
17 Dec 20
PRE 14A
Preliminary proxy
7 Dec 20
DEF 14A
Definitive proxy
1 Oct 20
DEF 14A
Definitive proxy
24 Sep 19
PRER14A
Preliminary revised proxy
23 Sep 19
PRE 14A
Preliminary proxy
13 Sep 19
Other
EFFECT
Notice of effectiveness
21 Jun 23
UPLOAD
Letter from SEC
16 Jun 23
CORRESP
Correspondence with SEC
16 Jun 23
EFFECT
Notice of effectiveness
10 Aug 20
CORRESP
Correspondence with SEC
31 Jul 20
CORRESP
Correspondence with SEC
27 Jul 20
UPLOAD
Letter from SEC
16 Jul 20
UPLOAD
Letter from SEC
24 Sep 19
CORRESP
Correspondence with SEC
23 Sep 19
UPLOAD
Letter from SEC
20 Sep 19